Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stewart M Spies

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Seminars in Nuclear Medicine|February 6, 2004
Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)Stewart M Spies
Journal of the American College of Cardiology|November 3, 2004
Left ventricular function during and after right ventricular pacingMaher Nahlawi, Michael Waligora, Stewart M Spies, et al.
Cancer|March 6, 2002
Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphomaGregory A Wiseman, Bryan Leigh, William D Erwin, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopeniaGregory A Wiseman, Bryan R Leigh, William D Erwin, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Seminars in Nuclear Medicine|February 6, 2004
Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)Stewart M Spies
Journal of the American College of Cardiology|November 3, 2004
Left ventricular function during and after right ventricular pacingMaher Nahlawi, Michael Waligora, Stewart M Spies, et al.
Cancer|March 6, 2002
Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphomaGregory A Wiseman, Bryan Leigh, William D Erwin, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopeniaGregory A Wiseman, Bryan R Leigh, William D Erwin, et al.
Pageof 1